Future scope of Peanut Allergy Vaccine Market
Peanut allergy is a relatively new indication with a significant unmet demand that has caught the industry’s attention as a market with a promising future.
Global Data anticipates a bright future for peanut allergy vaccine market in its upcoming study research, “Peanut Allergy: Opportunity Analysis and Forecasts to 2027.” Global Data estimates the peanut allergy market to grow nearly 1,700-fold between 2017 and 2027 across the eight main markets (8MM), which comprise the US, the 5EU (France, Germany, Italy, Spain, UK), Canada, and Australia.
This phenomenal rise is due to the anticipated introduction of four novel peanut immunotherapy medicines into a previously untapped market. Three oral immunotherapy (OIT) products—Aimmune Therapeutics’ AR-101, Prota Therapeutics’ PPOIT, and Camallergy’s CA-002—and one epicutaneous immunotherapy (DBV Technologies’ Viaskin Peanut) product are among the novel medicines.

Comments
Post a Comment